Creso Pharma Inc.

ASX: CPH, OTC: COPHF

Company Logo

Company Overview

Creso Pharma Inc. is a developer of cannabis and hemp-based therapeutic, nutraceutical and lifestyle products with wide patient and consumer reach for human and animal health.

The company announced its intent to acquire Halucenex Life Science in early 2021, which is a life science development company focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine. 

Halucenex operates a 6,000 sq. ft. medical facility in Windsor, Nova Scotia with six treatment rooms and a secure laboratory designed to perform psychedelic-assisted psychotherapy and clinical research.

Financial Highlights

$2,447,761

Revenue (ttm)

-$3,882,415

Gross Profit (ttm)

-$0.06

Diluted EPS (ttm)

Management Team

Mr. Adam Blumenthal B.Com., M.B.A.
Co-Founder & Non-Exec. Chairman

Mr. Boaz Wachtel M.A., M.D., MBA
Co-Founder & Non-Exec. Director

Mr. Christopher Grundy
Chief Financial Officer

Dr. James Anthony Ellingford M.B.A., Ph.D., PG(Corp Mgmt), D.Mgt, MBA, AICD
Exec. Director

Dr. Gian Trepp
Commercial & Marketing Director

Ms. Erlyn Saromines Dale A.C.I.S., B.Com., BCom., GradDipACG, AGIA, ACIS
Joint Company Sec.

Mr. Winton William Willesee BBus, BBus., CPA, DipEd, DipEd., PGDipBus, PGDi
Joint Company Sec.

Dr. Simon H. W. Buckingham
Consultant

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
0 (0%)

Insider Ownership
21%